FCER2 Negative
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT03946878) | M.D. Anderson Cancer Center | 2019-08-13 |
Track FCER2 Negative automatically
Every clearance here is in the API, with alerts when new ones post.